Background Observational studies report reduced colo rectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic eff ects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.
Introduction
People with monogenic predisposition to cancer off er an ideal focus for chemoprevention trials; the high probability of early tumours provides statistical power, and knowledge of genetic basis reduces heterogeneity while providing data relevant to patients whose sporadic cancers involve the same molecular pathway. Existing planned surveillance reduces cost and the relevance to family members encourages patient compliance. The Colorectal Adenoma/ carcinoma Prevention Programme (CAPP) was launched in 1990. CAPP1 investigated 200 young people with familial adenomatous polyposis. CAPP2, the fi rst largescale genetically targeted chemo prevention trial, focused on 1000 people with Lynch syndrome (also known as hereditary non-polyposis colon cancer or HNPCC), most carrying pathological DNA mismatch repair (MMR) gene variants, plus previously aff ected patients within families meeting the Amsterdam criteria. 1 Both trials used a factorial two-by-two design to assess two agents, aspirin and resistant starch, thought to protect against colorectal cancer. CAPP1 revealed a weakly signifi cant eff ect of aspirin on size of largest observed polyp and a signifi cant reduction in crypt length in participants given resistant starch. 2 In CAPP2 over 6 years, 937 people from 43 international centres commenced intervention. 3 After intervention, mean 29 months, there was no evidence that either agent aff ected development of colonic neoplasia, with most lesions being adenomas. 3 In view of cohort and casecontrol evidence of a protective eff ect of aspirin against colorectal cancer only after long-term exposure, 4 the original design of the CAPP2 study included doubleblind post-intervention follow-up for at least 10 years.
At the end of the intervention period, 3 128 participants had developed at least one adenoma and 23 had developed colorectal cancer. These were pooled for analysis as neoplasia since the primary endpoint of colorectal cancer was judged unlikely to be aff ected within 4 years in a population under colonoscopic surveillance. We now report the eff ect of aspirin on the incidence of colorectal cancer, the primary CAPP2 outcome, and other Lynch syndrome cancers as secondary outcomes. The baseline population of 861 participants (randomly assigned to aspirin or aspirin placebo in the randomised controlled trial) diff ers from our fi rst report, which was confi ned to those with an exit colonoscopy.
Methods

Trial design and participants
Between January, 1999, and March, 2005, 937 carriers of Lynch syndrome started intervention in the CAPP2 study 3, 5 and 746 were included in the end-of-intervention analysis (mean 29 months). Randomisation was in blocks of 16 in a two-by-two factorial design to aspirin (600 mg), aspirin placebo, resistant starch (30 g; Novelose, National Starch and Chemical Co, NJ, USA), and resistant starch placebo. Of the 937 participants, 427 were randomly assigned to aspirin, 434 to aspirin placebo, and the remaining recruits were not randomly assigned for the aspirin intervention, having opted not to participate in this part of the study (n=76; almost all due to perceived aspirin sensitivity or history of peptic ulceration). All participants who refused randomisation to the aspirin groups were randomly assigned to the resistant starch or resistant starch placebo intervention only (fi gure 1; webappendix p 1). Participants and investigators were masked to treatment allocation; one participant asked to be informed of her randomisation status after leaving the study. The study had a preplanned design for 10 years' follow-up; at the time of this analysis, the earliest enrolled participants had reached the 10-year threshold. All participants consented to long-term follow-up at recruitment and more detailed consent was obtained in the later stages of the study to ensure continued support.
The primary outcome of CAPP2 was development of colorectal cancer; the secondary outcomes were development of colorectal adenomas or the development of other Lynch syndrome-related cancers, or both. This analysis focused on 861 CAPP2 participants randomly assigned to aspirin or aspirin placebo from entry until the latest date for which the recruiters had information about cancer diagnosis-a timepoint usually corresponding to the date of last surveillance attendance. Our analysis included Lynch syndrome cancers that were included in the earlier report, 3 those that occurred subsequent to exit from the intervention phase, and all cancers that occurred in people without an exit colonoscopy, which excluded them from the statistical analysis in our earlier report. 3 As a result of dispersed international recruitment and because routine surveillance was provided by local health-care teams, records of adenoma occurrence in CAPP2 participants subsequent to the intervention phase are incomplete. Similarly, no details of adverse events were available postintervention; during the intervention phase, adverse events in the aspirin and placebo groups were similar (webappendix p 2). 3 There was also no signifi cant diff erence in compliance (ie, proportion of scheduled tablets not taken during the intervention phase) between the aspirin and aspirin placebo groups for participants with complete inter vention phase data (χ²(1)=1·27, p=0·20).
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Statistical analysis
This analysis was designed to test the primary hypothesis that aspirin would reduce the development of colorectal cancer (as primary outcome) and Lynch syndrome cancers (as secondary outcome) in 861 participants randomly assigned to aspirin (n=427) or aspirin placebo (n=434). The original protocol invited participants to continue with the original intervention for a further 2-year cycle after the initial 2 years. Two analytical approaches were taken: fi rst, time to fi rst occurrence of colorectal cancer (our original focus), which was examined with life-table methods and Cox proportional hazards; and second, Poisson regression modelling to investigate primary cancers at multiple anatomical sites, a feature of Lynch syndrome. Poisson regression analysis took into account the complete cancer history of the participant since randomisation, by contrast with the more restricted timeto-fi rst-event analysis.
For life-table analysis, end of follow-up was determined as the time of fi rst diagnosis of colorectal cancer, if the participant was aff ected, or the last recorded date at which clinical status was known. Analyses included Cox proportional hazards models to estimate sex-adjusted hazard ratios (HRs) and 95% CIs, and Kaplan-Meier curves to assess non-parametrically the outcome diff erences between the aspirin and aspirin placebo interventions. The assumption of proportional hazard was tested to assess compliance. For the Poisson regression analysis, incidence rate ratios (IRRs) for the eff ect of aspirin adjusted for sex were estimated from loglinear models for the number of primary cancers diagnosed after randomisation; exposure time was from randomisation until date of last known clinical status.
All analyses used Stata (version 10). Analyses were undertaken on an intention-to-treat basis (ie, intervention assigned at randomisation) and per protocol (restricting consideration to those taking aspirin [ endometrial, ovarian, pancreatic, small bowel, gall bladder, ureter, stomach, and kidney cancers and cancer of the brain were included. A fi nal analysis examined the total burden of Lynch syndrome-related cancers in participants who had been on intervention for at least 2 years (per protocol). All p values reported are two-sided (in keeping with the original sample-size calculation). This trial is registered, ISRCTN59521990.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Recruitment ran from Jan 1, 1999, to March 10, 2005 . The mean observation period was 55·7 months (range 1-128) and eight (1%) recruits were 10 years or more from randomisation by the time of the present analysis (table 1) . Times are measured from the date of randomisation. For 671 participants, we report both data for during the intervention and for longer follow-up, whereas for 190 we report on-intervention information only (webappendix p 3). Demographic data show no diff erences between those traced and not traced in this follow-up analysis with respect to age, sex, randomisation category, or geographical location (data not shown), although the development of a cancer could make followup reporting more complete. There were no signifi cant regional diff erences in incidence of colorectal cancer (data not shown; χ²(2)=5·03, p=0·08). Table 1 summarises the cancer burden in the study population. Overall, 40 people with postintervention information were diagnosed with colorectal cancer (13 of 342 allocated aspirin and 27 of 329 allocated aspirin placebo). Colo rectal cancer occurred in a further eight people among 190 individuals with information about the intervention phase only (fi ve of 85 patients on aspirin and three of 105 on aspirin placebo; fi gure 1; web appendix p 4).
Evidence has emerged of delayed protection by aspirin against cancer. For the whole postrandomisation period, the HR for colorectal cancer was 0·63 (95% CI 0·35-1·13, p=0·12), favouring protection in the aspirin group (table 2; fi gure 2). Five of 48 people who developed colorectal cancer each had two primary colon cancers. Of these, one had received aspirin and four aspirin placebo. Although the intention-to-treat time-to-event analysis showed a non-signifi cant protective eff ect of aspirin, the Poisson regression taking into account the fi ve participants with multiple primary colorectal cancer (53 cancers) indicated a protective eff ect (IRR 0·56, 95% CI 0·32-0·99, p=0·05). We re-estimated this pro tective eff ect with a per-protocol analysis and obtained similar results.
We examined outcomes in participants who took aspirin (or aspirin placebo) for a minimum of 2 years, defi ned as consumption of 1400 (300 mg) tablets (rounded down from a 2-year total [1461 tablets] to allow for early scheduling of the exit colonoscopy or occasional missed dosage). On the basis of this defi nition, 258 (60%) of those on aspirin and 250 (58%) of those on aspirin placebo were treated for 2 years or longer. Data are mean (SD; range) or n. *Two participants in the placebo group each had a colorectal cancer and another Lynch syndrome cancer; these participants were counted in the rows relating to both colorectal and other Lynch syndrome cancers; in the row relating to all Lynch syndrome cancers, these participants were counted only once. We explored the eff ect of compliance on outcome (which is important because non-compliance could be related to factors that also aff ect risk of colorectal cancer) using perprotocol analysis, and found that participants who took aspirin for 2 years or more had an incidence rate of 0·06 per 100 person-years compared with 0·13 per 100 person-years in those who took aspirin for less than 2 years. A similar analysis within the placebo group showed no signifi cant diff erence in incidence of colo rectal cancer between participants who took aspirin placebo for 2 years or more (0·14 per 100 person years) compared with those who took aspirin placebo for less than 2 years (0·10 per 100 person years; data not shown).
We also undertook a planned secondary analysis with other Lynch syndrome cancers as the outcome. 18 participants developed endometrial cancer, of whom fi ve were randomly assigned to aspirin and 13 to aspirin placebo; in total, 38 participants developed cancer at a site other than the colorectum (additionally, two participants had colorectal and another Lynch syndrome cancer) of whom 16 were randomly assigned to aspirin and 22 to aspirin placebo (webappendix p 5). The HR for those randomly assigned to aspirin was 0·63 (95% CI 0·34-1·19 p=0·16, table 2; webappendix p 6) and the IRR was 0·63 (95% CI 0·34-1·16 p=0·14) compared with the aspirin placebo group. Per-protocol analysis showed an HR for those who had taken aspirin for 2 years or more of 0·47 (95% CI 0·21-1·06, p=0·07) with an IRR of 0·49 (95% CI 0·23-1·05 p=0·07; table 2). Table 2 shows the combined analysis of all Lynch syndrome cancers including colorectal cancer. On intention-to-treat analysis, the HR was 0·65 (95% CI 0·42-1·00, p=0·05) and IRR was 0·59 (95% CI 0·39-0·90, p=0·01), and in the per-protocol analysis the HR was 0·45 (0·26-0·79, p=0·005; fi gure 3) and the IRR was 0·42 (0·25-0·72, p=0·001), supporting the protective eff ect of aspirin. Cox proportional hazards model analysis by cumulative aspirin consumption suggested a doseresponse eff ect, which was signifi cant for non-colorectal Lynch syndrome cancers (p=0·03) and Lynch syndrome cancers overall (p=0·007), but not for colorectal cancer (p=0·06; table 2). Corresponding outcomes from the Poisson regression analysis were also signifi cant (p=0·03 for non-colorectal Lynch syndrome cancers, p=0·002 for Lynch syndrome cancers overall, and p=0·03 for colorectal cancer).
The CAPP2 study included a group of participants who chose not to be randomly assigned for aspirin and who were randomly assigned for the resistant starch intervention only. To establish whether the apparent protective eff ect of aspirin might be attributable to unexpectedly high numbers of cancers in the aspirin placebo group, we tested the risk of colorectal cancer for the non-randomised group (resistant starch or resistant starch placebo only) compared with the aspirin placebo group. The HR for colorectal cancer in this group was 1·4 times higher compared with the aspirin placebo group (p=0·4). This fi nding supports the protective eff ect of aspirin.
Where possible, details of adenoma development were obtained in the postintervention period. Although incomplete, these data, gathered by masked contributors, revealed no apparent eff ect of aspirin on numbers of participants who developed adenomas subsequent to the intervention phase-ie, 51 and 48 in the aspirin and aspirin placebo groups, respectively.
Hazard ratio
Incidence rate ratio † 95% CI* p value 95% CI p value
Colorectal cancer
Intention-to-treat analysis
Aspirin versus aspirin placebo 0·63 (0·35-1·13) 0·12 0·56 (0·32-0·99) 0·05
Per-protocol analysis . †Incidence rate ratio from Poisson regression. ‡The threshold for 2 years' intervention was consumption of more than 1400 aspirin tablets; rounded down from a 2-year total of 1461 tablets to allow for early scheduling of the exit colonoscopy or occasional missed dosage. §Units of 100 aspirin=total number of aspirin taken divided by 100. The data were analysed according to the underlying MMR gene defect; colorectal cancer was reported with equal frequency in participants carrying MLH1 and MSH2 mutations (6·0% and 7·0%, respectively), and none of the MSH6 mutation carriers developed colorectal cancer, in keeping with the anticipated milder phenotype (webappendix p 7). The remaining 163 recruits were diagnosed on the basis of Amsterdam Criteria 1 and had been treated for a Lynch syndrome-related neoplasia. Of these, seven (4%) developed colorectal cancer. Overall, there was no evidence of diff erence in incidence of colorectal cancer by presence of proven germ-line mutation (χ²(2)=3·1, p=0·38).
18 (34%) of 53 colorectal cancers diagnosed in aspirin or aspirin placebo groups were Dukes stage A, 21 (40%) Dukes B, ten (19%) had Dukes C and D, and four (8%) were unknown. 27 (51%) tumours were located in the ascending colon, transverse colon, and splenic fl exure, six (11%) in the descending colon, 12 (23%) in the sigmoid and rectum, and eight (15%) were unknown. There was no signifi cant diff erence in staging (χ²(3)=2·92, p=0·40) and tumour location (χ²(3)=0·08, p=0·99) between aspirin and aspirin placebo groups.
Discussion
The CAPP2 study was the fi rst double-blind randomised controlled trial of aspirin chemoprevention with cancer as the primary endpoint. The outcome is consistent with more than two decades of observational data showing that risk of colorectal cancer is halved in regular aspirin consumers 7 and recent long-term follow-up of aspirin trials for cardiovascular disease prevention showing that dosing with 75 mg or more of aspirin per day for several years reduced deaths from gastrointestinal cancers, particularly involving the proximal colon. 8, 9 This concept of delayed cancer chemoprevention was apparent in observational studies, in which protection against cancer in regular aspirin users took about 10 years to emerge. 4, 7 This eff ect was presumed to be dependent on continued aspirin exposure, but in the cardiovascular disease trials, treatment ended at a mean of 6 years. Analysis of cancerrelated death in eight trials 10 revealed signifi cant protection in participants allocated aspirin for 4 years or more, but only when followed up for a further 5 years. Our fi ndings support the hypothesis of a delayed eff ect of aspirin on colorectal cancer by showing that aspirin reduced incidence of colorectal cancer with the eff ect becoming apparent after 3-4 years from the start of aspirin intervention, a diff erence consistent with faster cancer development in those with Lynch syndrome (panel). 11, 12 In intention-to-treat analysis, Poisson regression analysis, which incorporates more of the follow-up information than the time-to-event analysis (ie, total number of cancers in follow-up period vs time to fi rst cancer), showed similar estimates of the protective eff ect but, as anticipated, greater statistical signifi cance. The per-protocol analysis showed a similar eff ect. Aspirin placebo 600 mg aspirin
In keeping with the eff ect of aspirin on non-colonic Lynch syndrome cancers (endometrial cancer, ovarian cancer, pancreatic cancer, and cancer of the brain, small bowel, gall bladder, ureter, stomach, and kidney) in our trial, Rothwell and colleagues 10 reported that aspirin treatment reduced risk of death from several non-colonic solid cancers including oesophageal, pancreatic, brain, lung, stomach, and prostate cancer. Whether Lynch syndrome cancers are more responsive to aspirin is unclear, although in CAPP2 non-Lynch syndrome extracolonic cancers seemed unaff ected by aspirin intervention. A weakness of our international study was the inability to collect a comprehensive series of tumour blocks to confi rm that tumour development was related to the germline MMR mutation.
Our discovery of substantial protection by aspirin against colorectal cancer and other Lynch syndrome cancers is in striking contrast with our earlier report 3 of no eff ect of aspirin on large-bowel neoplasia. Taken together, these fi ndings might help to explain the marked disparity between the 50% cancer reduction reported in observational studies and the outcomes of randomised adenoma prevention trials, which have shown at best a small reduction eff ect; meta-analysis revealed a pooled risk ratio of any adenoma for any dose of aspirin versus placebo of 0·83 (95% CI 0·72-0·96). 13 Our recent CAPP1 report 2 in carriers of familial adenomatous polyposis revealed a small eff ect of aspirin on adenoma progression, but no demonstrable eff ect on polyp number, albeit using insensitive methods of analysis. In view of the CAPP2 fi ndings, revisiting the CAPP1 participants to see whether aspirin has long-term eff ects on their disease progression will be interesting.
Several important questions remain: (1) whether aspirin targets the minority of adenomas with the greatest malignant potential; (2) whether some Lynch syndrome colorectal cancers arise from lesions other than adenomas; 14 and (3) why do some tumours seem to be resistant to the eff ects of aspirin? The mechanism by which aspirin suppresses cancer development long after cessation of exposure to the drug is unclear. The assumed primary action of anti-infl ammatory drugs on COX2 in colonic tumours 15 is unlikely to be the primary mechanism. The rapid progression from adenoma to carcinoma in Lynch syndrome 12 makes it likely that many screendetected cancers would have begun to develop after aspirin intervention ended. Aspirin might be proapoptotic at early stages of colorectal cancer development, perhaps preceding adenoma formation. Ruschoff and colleagues 16, 17 reported reduced micro satellite instability and increased apoptosis in MMR-defi cient cells exposed to aspirin and argued that aspirin might induce genetic selection for microsatellite stability in a subset of MMR-defi cient cells. Aspirin might delete those aberrant stem cells most likely to progress rapidly to cancer. Analysis of the conditional MSH2 knockout mouse, reported recently to survive signifi cantly longer when exposed to aspirin, 18 might shed light on the mechanism.
Despite regular colonoscopy, almost one in 14 participants not taking aspirin in CAPP2 developed colorectal cancer in less than 5 years, emphasising the need for additional prevention strategies. Our results, taken in conjunction with recent research, provide a basis for recommendation of aspirin chemoprevention in Lynch syndrome as standard of care. CAPP3 will seek to establish the optimum dose and duration of aspirin treatment. 
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Systematic review
We have accessed, using PubMed and our professional networks, all publications related to use of aspirin as a cancer chemopreventive agent and we have reviewed all research studies addressing therapeutic and preventive interventions in hereditary colorectal cancer in general and Lynch syndrome in particular. Search terms used were "hereditary colorectal cancer", "Lynch syndrome", or "HNPCC", and "therapeutic", "chemoprevention", "prevention", "aspirin", or "NSAID". There is extensive support to the eff ect that regular aspirin use reduces the cancer burden from observational studies 7 and a meta-analysis of follow-up registry data derived from participants in randomised controlled trials of aspirin as a means of preventing occlusive vascular disease. 10 Randomised trials based on prevention of colorectal adenomas as a biomarker of cancer showed an equivocal eff ect, but meta-analysis revealed a small but signifi cant benefi t.
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Interpretation CAPP2 is the fi rst randomised trial of aspirin as a chemopreventive agent with cancer as the primary endpoint. In the context of the published literature, the trial provides clear evidence that aspirin is an eff ective chemopreventive agent in hereditary cancer with an eff ect equivalent to that achieved with surveillance colonoscopy. The case for prescription of aspirin to this high-risk group is clear. The mechanism of this delayed action and, consequently, the optimum dose and duration of treatment remain to be established. A worldwide dose inferiority study is planned, but will take several years since adenomas are not a reliable biomarker of eff ect. In the meantime, clinicians should consider aspirin prescription for all individuals judged to be at high risk of colorectal cancer, but taking appropriate measures to minimise adverse eff ects. Indirect evidence suggests that a lower dose of aspirin than was used here will have a protective eff ect and its use would not compromise future involvement in a masked comparison of low-dose aspirin with 600 mg. CAPP3 will compare the eff ect of diff erent aspirin doses in Lynch syndrome.
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